Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

BACKGROUND: ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated. Here we report results from a comparative clinical study that evaluated the efficacy and safety of ABP...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Arthritis Res Ther
Hlavní autoři: Genovese, Mark C., Sanchez-Burson, Juan, Oh, MyungShin, Balazs, Eva, Neal, Jeffrey, Everding, Andrea, Hala, Tomas, Wojciechowski, Rafal, Fanjiang, Gary, Cohen, Stanley
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7098142/
https://ncbi.nlm.nih.gov/pubmed/32216829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-020-2142-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky